DPP4 and Insulin resistance: Clinical trials studying the effect of DPP-4 inhibitors on GDM have demonstrated a reduction in insulin resistance, alleviation of the symptoms associated with hyperglycemia, reduction in fasting plasma glucose and serum insulin, and downregulation of a biomarker indicative of glucose intolerance [15].